Geneos Wealth Management’s BioXcel Therapeutics BTAI Stock Holding History

Geneos Wealth Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-9	Closed	-$6K	–	2898
2020 Q3	$6K	Buy	9 +3	+50%	+$2.25K	﹤0.01%	2105
2020 Q2	$5K	Hold	6	–	–	﹤0.01%	2129
2020 Q1	$2K	Buy	+6	New	+$2.16K	﹤0.01%	2234
2019 Q4	–	Sell	-13	Closed	-$1K	–	2545
2019 Q3	$1K	Hold	13	–	–	﹤0.01%	2371
2019 Q2	$2K	Hold	13	–	–	﹤0.01%	2296
2019 Q1	$1K	Buy	+13	New	+$1.6K	﹤0.01%	2303

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Geneos Wealth Management's BTAI Position: Q4 2020 in Review

Geneos Wealth Management sold out of BioXcel Therapeutics (BTAI) in Q4 2020, closing a stake of 9 shares — an estimated $6K sold.

Geneos Wealth Management first reported a position in BTAI in Q1 2019 and held it in 6 quarters. The position peaked at $6K in Q3 2020. 117 funds tracked by Wall St. Rank hold BTAI as of Q4 2020.

Geneos Wealth Management reported no remaining BioXcel Therapeutics position as of Q4 2020 after selling out during the quarter.
Geneos Wealth Management sold 9 BioXcel Therapeutics shares in Q4 2020, an estimated $6K.
Geneos Wealth Management first reported a position in BioXcel Therapeutics in Q1 2019 and held it in 6 quarters.
Geneos Wealth Management's BioXcel Therapeutics position peaked at $6K in Q3 2020.
117 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2020.

Based on Geneos Wealth Management's 13F filing for Q4 2020, filed 19 May 2021.